Bioteque Bilan de santé

Santé financière contrôle des critères 5/6

Bioteque possède un total de capitaux propres de NT$3.3B et une dette totale de NT$483.7M, ce qui porte son ratio d'endettement à 14.7%. Son actif total et son passif total sont NT$4.5B et de NT$1.2B. L'EBIT de Bioteque est NT$646.9M ce qui fait que son ratio de couverture des intérêts -208.6. Elle dispose de liquidités et de placements à court terme de NT$1.4B.

Informations clés

14.7%

Ratio d'endettement

NT$483.68m

Dette

Ratio de couverture des intérêts	-208.6x
Argent liquide	NT$1.44b
Fonds propres	NT$3.29b
Total du passif	NT$1.20b
Total des actifs	NT$4.49b

Mises à jour récentes de la santé financière

Bioteque (GTSM:4107) Has A Rock Solid Balance Sheet

Jan 10

Recent updates

A Look At The Fair Value Of Bioteque Corporation (GTSM:4107)

Apr 26

Should You Buy Bioteque Corporation (GTSM:4107) For Its Dividend?

Mar 29

Bioteque Corporation's (GTSM:4107) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 11

Are Bioteque Corporation's (GTSM:4107) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Dec 10

Will Bioteque (GTSM:4107) Multiply In Value Going Forward?

Nov 22

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4107 ( NT$2.1B ) dépassent ses passifs à court terme ( NT$528.8M ).

Passif à long terme: Les actifs à court terme de 4107 ( NT$2.1B ) dépassent ses passifs à long terme ( NT$675.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4107 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4107 est passé de 3.3% à 14.7% au cours des 5 dernières années.

Couverture de la dette: La dette de 4107 est bien couverte par le flux de trésorerie opérationnel ( 147.3% ).

Couverture des intérêts: 4107 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Bioteque Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Bioteque (GTSM:4107) Has A Rock Solid Balance Sheet

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.08 (vs NT$2.11 in 3Q 2023)

Bioteque Corporation to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: EPS: NT$1.80 (vs NT$1.48 in 2Q 2023)

Bioteque Corporation to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$4.50 per share

First quarter 2024 earnings released: EPS: NT$1.81 (vs NT$1.42 in 1Q 2023)

Bioteque Corporation Announces Cash Dividend, Payable on August 30, 2024

Bioteque Corporation to Report Q1, 2024 Results on May 09, 2024

Bioteque Corporation to Report Q1, 2024 Results on May 09, 2024

Bioteque Corporation Announces Board Changes

Full year 2023 earnings released: EPS: NT$6.53 (vs NT$7.12 in FY 2022)

Bioteque Corporation, Annual General Meeting, Jun 19, 2024

Third quarter 2023 earnings released: EPS: NT$2.11 (vs NT$1.93 in 3Q 2022)

Now 21% undervalued after recent price drop

Upcoming dividend of NT$4.50 per share at 4.2% yield

Bioteque Corporation Announces Chief Internal Auditor Changes

Now 20% undervalued

Bioteque Corporation Announces Executive Appointments

Full year 2022 earnings released: EPS: NT$7.12 (vs NT$6.22 in FY 2021)

Bioteque Corporation Announces Executive Changes

Third quarter 2022 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations

Bioteque Corporation Announces Change of Vice Chairman

Bioteque Corporation Announces Resignation of Tang-Lung Hsu as Natural-Person Director

Upcoming dividend of NT$4.50 per share

Second quarter 2022 earnings: EPS exceeds analyst expectations

Bioteque Corporation Appoints Yiu-Cho Chin as Member of the Fifth Term of Compensation Committee

Bioteque Corporation Announces Resignation of Ren-Fang Li as Independent Director

Bioteque Corporation Appoints Members of the Fifth Term of Compensation Committee

Bioteque Corporation Announces Board Changes

First quarter 2022 earnings released: EPS: NT$1.76 (vs NT$1.74 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$1.29 (vs NT$1.75 in 3Q 2020)

Upcoming dividend of NT$4.00 per share

Second quarter 2021 earnings released: EPS NT$1.31 (vs NT$1.56 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$1.74 (vs NT$1.57 in 1Q 2020)

A Look At The Fair Value Of Bioteque Corporation (GTSM:4107)

Should You Buy Bioteque Corporation (GTSM:4107) For Its Dividend?

Full year 2020 earnings released: EPS NT$7.05 (vs NT$6.70 in FY 2019)

Bioteque Corporation Approves Dividend Distribution of 2020 Profits

Bioteque Corporation's (GTSM:4107) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

New 90-day low: NT$125

The Trends At Bioteque (GTSM:4107) That You Should Know About

Update: Bioteque (GTSM:4107) Stock Gained 51% In The Last Three Years

New 90-day low: NT$126

Estimating The Intrinsic Value Of Bioteque Corporation (GTSM:4107)

Bioteque (GTSM:4107) Has A Rock Solid Balance Sheet

New 90-day low: NT$130

Does Bioteque Corporation (GTSM:4107) Have A Place In Your Dividend Portfolio?

Are Bioteque Corporation's (GTSM:4107) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Will Bioteque (GTSM:4107) Multiply In Value Going Forward?

Third quarter 2020 earnings released: EPS NT$1.75

Revenue misses expectations

New 90-day low: NT$132

New 90-day low - NT$133

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines